Trial · NCT00682565
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) | Mid Dose Active Drug | 0 | Participants | ||
| Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) | High Dose Active Drug | 0 | Participants | ||
| Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) | All Placebo | 1 | Participants | ||
| Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B | Mid Dose Active Drug | 4 | Participants | ||
| Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B | High Dose Active Drug | 2 | Participants | ||
| Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B | All Placebo | 1 | Participants | ||
| Increase in Exercise Duration During ETT-3 vs. ETT-B | Mid Dose Active Drug | 41.5 | Standard Deviation 113.1 | seconds | |
| Increase in Exercise Duration During ETT-3 vs. ETT-B | High Dose Active Drug | 40.5 | Standard Deviation 70.6 | seconds | |
| Increase in Exercise Duration During ETT-3 vs. ETT-B | All Placebo | 60.1 | Standard Deviation 71.2 | seconds | |
| Participants Stopping ETT-3 for Angina at Any Stage | Mid Dose Active Drug | 0 | Participants | ||
| Participants Stopping ETT-3 for Angina at Any Stage | High Dose Active Drug | 7 | Participants | ||
| Participants Stopping ETT-3 for Angina at Any Stage | All Placebo | 2 | Participants | ||
| Participants With 1 mm ST Segment Depression During ETT-3 | Mid Dose Active Drug | 0 | Participants | ||
| Participants With 1 mm ST Segment Depression During ETT-3 | High Dose Active Drug | 1 | Participants | ||
| Participants With 1 mm ST Segment Depression During ETT-3 | All Placebo | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00682565/results